m-RNA Synthesis Service Global Market Report 2025

The mRNA synthesis service market size has grown strongly in recent years. It will grow from $4.54 billion in 2024 to $4.99 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. Growth during this historical period was driven by the rising demand for personalized medicine and gene therapies, the expansion of clinical trials, increased prevalence of infectious diseases, heightened investment in biotechnology, and an intensified focus on vaccine development.

The mRNA synthesis service market size is expected to see strong growth in the next few years. It will grow to $7.22 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. This anticipated growth is attributed to the increasing use of mRNA therapies, broader applications of mRNA technology, heightened focus on mRNA treatments for autoimmune diseases, sustained demand for mRNA-based vaccines, and rising need for custom mRNA synthesis solutions. Notable trends expected during this period include innovations in RNA polymerase enzyme engineering, development of next-generation mRNA vaccines, automation in mRNA manufacturing, personalized mRNA therapeutics, and the integration of AI and machine learning in mRNA design.

The increasing focus on personalized medicine is expected to propel the growth of the mRNA synthesis service market going forward. Personalized medicine refers to a medical approach that tailors treatment and healthcare decisions to an individual’s genetic makeup, lifestyle, and environment. This approach is gaining momentum due to advancements in genomic sequencing, which allow for more precise identification of individual genetic variations linked to disease and treatment response. mRNA synthesis services support the growing emphasis on personalized medicine by enabling the rapid and precise production of mRNA-based therapies tailored to an individual’s genetic profile, resulting in more effective and targeted treatments. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments in 2023 for patients with rare diseases, up from 6 in 2022. Among these, seven were cancer drugs, and three addressed other diseases and conditions. As such, the increasing focus on personalized medicine is driving the expansion of the mRNA synthesis service market.

Major companies operating in the mRNA synthesis service market are focusing on developing innovative solutions, such as RNA polymerase innovations, to improve the efficiency, yield, and safety of mRNA synthesis. RNA polymerase innovations involve the development of advanced enzymes that enhance the transcription process, reduce side effects like double-stranded RNA formation, and improve the overall quality of mRNA used in vaccines and therapeutics. For instance, in March 2025, Primrose Bio Inc., a US-based biotechnology company, introduced Prima RNApols to enhance the efficiency and scalability of mRNA synthesis. This enzyme offers enhanced processivity and high-fidelity transcription, enabling the production of longer and more stable mRNA strands with lower error rates. Its robust performance in in vitro transcription systems minimizes impurities and increases yield, providing a reliable and scalable solution for companies developing mRNA-based drugs. This innovation holds particular significance in personalized medicine, where accurate and efficient mRNA synthesis is critical.

In December 2024, Novo Holdings A/S, a Denmark-based investment firm, acquired Catalent Inc. for $16.5 billion. This acquisition is aimed at strengthening Novo Holdings’ position in the life sciences sector by boosting its capabilities in drug development and supply while promoting sustainable value creation through an engaged ownership model. Catalent Inc., a US-based company, specializes in mRNA synthesis services for therapeutics and vaccines.

Major players in the m-rna synthesis service market are Thermo Fisher Scientific Inc., Danaher Corporation, AGC Biologics Inc., Eurofins Scientific SE, Lonza Group AG, Catalent Inc., Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., GenScript Biotech Corporation, Azenta Inc., Genewiz Inc., New England Biolabs Inc., TransGen Biotech Co. Ltd., Creative Biolabs Inc., Bioneer Corporation, Aldevron LLC, eTheRNA immunotherapies NV, Bio-Synthesis Inc., TriLink BioTechnologies LLC, and APExBIO Technology LLC.

North America was the largest region in the m-RNA synthesis service market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mRNA synthesis service report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mRNA synthesis service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A messenger ribonucleic acid (mRNA) synthesis service involves the production of custom mRNA molecules through in vitro transcription using a provided deoxyribonucleic acid (DNA) template. These services are utilized for various purposes, including vaccine development, gene therapy, and research in protein expression and functional genomics.

The primary types of mRNA synthesis services include mRNA vaccine synthesis and mRNA drug synthesis. mRNA vaccine synthesis refers to the laboratory process of generating mRNA sequences that guide cells to produce a specific protein, which triggers an immune response to combat infectious diseases. These services support several application areas such as vaccine development, therapeutic development, research and development, and diagnostics. The end-users of these services include pharmaceutical companies, biotechnology firms, academic and research institutions, and contract research organizations (CROs).

The mRNA synthesis service market research report is one of a series of new reports that provides mRNA synthesis service market statistics, including the mRNA synthesis service industry global market size, regional shares, competitors with the mRNA synthesis service market share, detailed mRNA synthesis service market segments, market trends, and opportunities, and any further data you may need to thrive in the mRNA synthesis service industry. This mRNA synthesis service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mRNA synthesis service market consists of revenues earned by entities by providing services such as template DNA preparation, codon optimization, stability and storage testing, and regulatory support for clinical applications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.